

Special Issue

Lung Adenocarcinoma: Screening and Surgical Treatment

Message from the Guest Editors

While male incidence and fatality rates have decreased marginally in recent years, female rates continue to grow. Disseminated illness, including nodal and distant metastases, outnumbered localized disease by more than threefold. Due to the predictive significance of the tumor stage at diagnosis, a high prevalence of advanced tumor stages at diagnosis contributes to lung cancer's high mortality.

Recent therapy advances, such as checkpoint inhibitors or immunotherapy, have the potential to increase survival. Despite this, they only cure a minority of patients, and long-term survivors of metastatic illness are uncommon. The stage of the tumor continues to have the most significant impact on overall and cancer-specific survival. To truly enhance survival, patients must be detected early in the course of the disease. The results of lung cancer screening trials are encouraging, indicating that individuals with lung cancer have an improved survival rate, owing primarily to a shift in tumor stages at the time of discovery. Increased lung nodules for histopathologic examination and early tumor stages result in increased patient volume and workload for thoracic surgical units.

Guest Editors

Prof. Dr. Lorenzo Spaggiari

1. Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milano, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, 201222 Milan, Italy

Dr. Luca Bertolaccini

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy

Deadline for manuscript submissions

closed (1 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/90470

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)